gastroesohageal reflux disease
Conditions
Interventions
Vonoprazan Fumarate tablets 20 mg/day for 4 weeks p.o.
Sponsors
Ishihara Gastroenterology clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligible, enrolled patients were who had judged to be appropriate to start the treatment of PPIs defined by GerdQ questionnaire and who had judged having insufficient therapeutic effects also defined by GerdQ despite continuing the conventional PPIs for four weeks or more.
Exclusion criteria
Exclusion criteria: The patient that a serious heart, liver, renal function disorder, a patient developing a malignant neoplasm, a gastrointestinal tract resection, stomach esophagus junction rebuilding art, a patient having the past of the straying neurolysis, the combination taboo medicine of VFT
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment reactivity by GerdQ after 20 mg Vonoprazan Fumarate tablets (VFT)administration 4 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Reflux symptom disapearance by GERDQ and Frequency Scale for the symptom of GERD (FSSG) and acid reflux related conditions score by FSSG | — |
Countries
Japan
Contacts
Public ContactIshihara shinichi
Ishihara Gastroenterology clinic internalmedicine
Outcome results
None listed